Supplemental Fibrinogen Restores Platelet Inhibitor-Induced Reduction in Thrombus Formation without Altering Platelet Function: An In Vitro Study
Research article published in Thrombosis and haemostasis (2020)
Abstract
BACKGROUND: For patients treated with dual antiplatelet therapy, standardized drug-specific 3-to-7 day cessation is recommended prior to major surgery to reach sufficient platelet function recovery. Here we investigated the hypothesis that supplemental fibrinogen might mitigate the inhibitory effects of antiplatelet therapy. METHODS AND RESULTS: To this end blood from healthy donors was treated in vitro with platelet inhibitors, and in vitro thrombus formation and platelet activation were assessed. Ticagrelor, acetylsalicylic acid, the combination of both, and tirofiban all markedly attenuated the formation of adherent thrombi, when whole blood was perfused through collagen-coated microchannels at physiological shear rates. Addition of fibrinogen restored in vitro thrombus formation in the presence of antiplatelet drugs and heparin. However, platelet activation, as investigated in assays of P-selectin expression and calcium flux, was not altered by fibrinogen supplementation. Most importantly, fibrinogen was able to restore in vitro thrombogenesis in patients on maintenance dual antiplatelet therapy after percutaneous coronary intervention. CONCLUSION: Thus, our in vitro data support the notion that supplementation of fibrinogen influences the perioperative hemostasis in patients undergoing surgery during antiplatelet therapy by promoting thrombogenesis without significantly interfering with platelet activation.
Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.
Zusammenfassung
For patients treated with dual antiplatelet therapy, standardized drug-specific 3-to-7 day cessation is recommended prior to major surgery to reach sufficient platelet function recovery.
Warum dies für die Hirudotherapie relevant ist
Diese In-vitro-Studie untersuchte, ob supplementiertes Fibrinogen die Thrombusbildung im Vollblut gesunder Spender, die mit Thrombozyteninhibitoren (Ticagrelor, Acetylsalicylsäure, Tirofiban und Kombinationen) plus Heparin behandelt wurden, unter Verwendung kollagenbeschichteter Mikrokanäle bei physiologischen Scherraten wiederherstellen konnte. Fibrinogen stellte die Thrombogenese wieder her, ohne die Marker der Thrombozytenaktivierung (P-Selektin, Kalziumflux) zu verändern, und zeigte ähnliche restaurative Effekte bei Patienten unter dauerhafter dualer Thrombozytenaggregationshemmung nach perkutaner Koronarintervention. Die Zusammenfassung erwähnt weder Hirudin, aus Blutegeln stammende Komponenten noch therapeutisches Blutegel-Setzen; Heparin – nicht Hirudin – ist das untersuchte Antikoagulans, wodurch die Relevanz dieses Artikels für das ASH-Gebiet allenfalls peripher ist.
Zitation
Supplemental Fibrinogen Restores Platelet Inhibitor-Induced Reduction in Thrombus Formation without Altering Platelet Function: An In Vitro Study
Brnthaler T et al. · Thrombosis and haemostasis, 2020
Verwandter klinischer Kontext
Erfahren Sie, wie diese Forschung mit der klinischen Praxis verknüpft ist
Zur ASH-Bibliothek hinzugefügt: May 27, 2026 · Letzte Aktualisierung der Website: 18. Juni 2026